# CREBBP

Source: https://onco.cc/targets/crebbp/  
OnCo record `crebbp` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CREBBP (CREB-binding protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Bladder & urothelial cancer, Leukaemia and 5 more.

## Summary

Acetylates histones, giving a specific tag for transcriptional activation. Mediates acetylation of histone H3 at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac, respectively). Also acetylates non-histone proteins, like DDX21, FBL, IRF2, MAFG, NCOA3, POLR1E/PAF53 and FOXO1.

CIViC holds 5 clinical evidence items and 0 assertions across 4 variants, naming MTOR Inhibitor, C646, HDAC Inhibitor OBP-801 and Therapeutic Glucocorticoid. Open Targets scores its association with cancer at 0.83 (direct and indirect evidence; datatypes clinical 0.16, affected pathway 0.84, literature 0.99, genetic association 0.20, somatic mutation 0.97, animal model 0.58). IntOGen calls it a driver in 42 cohorts (12 activating, 29 loss-of-function), covering Acute Lymphoblastic Leukaemia, Basal Cell Carcinoma, Bladder/Urinary Tract, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: CREB binding lysine acetyltransferase ; CREB-binding protein; KAT3A
- Tags: cancer-genes-wave
- Symbol: CREBBP
- Class: transcription
- Biology: Acetylates histones, giving a specific tag for transcriptional activation. Mediates acetylation of histone H3 at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac, respectively). Also acetylates non-histone proteins, like DDX21, FBL, IRF2, MAFG, NCOA3, POLR1E/PAF53 and FOXO1. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-BMAL1 and CLOCK-BMAL1 heterodimers. Location: Cytoplasm; Nucleus (UniProt). Locus 16p13.3 (HGNC).
- Where found: Non-Hodgkin lymphoma: Open Targets association 0.74 with non-Hodgkin lymphoma (MONDO_0018908); CIViC evidence names this disease; Bladder & urothelial cancer: Open Targets association 0.66 with urinary bladder cancer (MONDO_0001187); IntOGen driver in 7 cohorts (BLADDER, BLCA, UTUC); Leukaemia: Open Targets association 0.65 with leukaemia (MONDO_0005059); Neuroendocrine tumours: Open Targets association 0.60 with neuroendocrine neoplasm (MONDO_0019496); IntOGen driver in 1 cohort (NETNOS); Oesophageal cancer: Open Targets association 0.54 with oesophageal cancer (MONDO_0007576); IntOGen driver in 2 cohorts (ESCA); Breast cancer: Open Targets association 0.51 with breast cancer (MONDO_0007254); IntOGen driver in 2 cohorts (BRCA)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.16; IntOGen calls it an activating (Act) driver in 12 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 29 cohorts; CIViC holds 5 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:2348: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2348
- UniProt Q92793: https://www.uniprot.org/uniprotkb/Q92793/entry
- NCBI Gene 1387: https://www.ncbi.nlm.nih.gov/gene/1387
- Ensembl ENSG00000005339: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000005339

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)

---
JSON: https://onco.cc/api/v1/entities/crebbp.json